Title

Influence of bestatin, an inhibitor of aminopeptidases, on T and B lymphocyte subsets in mice

Journal title

Polish Journal of Veterinary Sciences

Yearbook

2011

Issue

No 3

Authors

Lis, M. ; Szczypka, M. ; Suszko, A. ; Obmińska-Mrukowicz, B.

Divisions of PAS

Nauki Biologiczne i Rolnicze

Publisher

Polish Academy of Sciences Committee of Veterinary Sciences ; University of Warmia and Mazury in Olsztyn

Date

2011

Identifier

DOI: 10.2478/v10181-011-0059-y ; ISSN 1505-1773

Source

Polish Journal of Veterinary Sciences; 2011; No 3

References

F Abe (1990), Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice, Cancer Immunol Immunother, 32, 75, doi.org/10.1007/BF01754202 ; B Bauvois (2006), Aminopeptidase-N/CD13 (EC 3.4.11.2.) inhibitors: chemistry, biological evaluations and therapeutic prospects, Med Res Rev, 26, 88, doi.org/10.1002/med.20044 ; B Dunlap (1984), Effect of bestatin on in vitro responses of murine lymphocytes to T-cell stimuli, Scand J Immunol, 20, 237, doi.org/10.1111/j.1365-3083.1984.tb00997.x ; E Favaloro (1993), CD13 (GP 150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated, Exp Hematol, 21, 1695. ; Y Hirayama (2003), Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients-effects, complications and long-term survival, Gan To Kagaku Ryoho, 30, 1113. ; E Ichimura (2006), Immunohistochemical expression of aminopeptidase N (CD13) in human lung squamous cell carcinomas, with special reference to bestatin adjuvant therapy, Pathol Int, 56, 296, doi.org/10.1111/j.1440-1827.2006.01963.x ; Y Ichinose (2003), Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma, J Natl Cancer Inst, 95, 605, doi.org/10.1093/jnci/95.8.605 ; M Ishizuka (1980a), Effect of bestatin on mouse immune system and experimental murine tumors, J Antibiot (Tokyo), 33, 642, doi.org/10.7164/antibiotics.33.642 ; M Ishizuka (1980b), Mitogenic effect of bestatin on lymphocytes, J Antibiot (Tokyo), 33, 653. ; C Jarstrand (1981), Bestatin, a new immunomodulator, enhances migration and phagocytosis of human granulocytes in vitro, J Clin Lab Immunol, 5, 67. ; K Jung (1984), Characterization of particulate and soluble variants of the brush-border enzymes alanine aminopeptidase, alkaline phosphatase and gamma-glutamyltransferase in human urine, Biomed Biochim Acta, 43, 1357. ; B Lkhagvaa (2008), Bestatin, an inhibitor for aminopeptidases, modulates the production of cytokines and chemokines by activated monocytes and macrophages, Cytokine, 44, 386, doi.org/10.1016/j.cyto.2008.10.011 ; A Look (1989), Human myeloid plasma membrane glycoprotein CD 13 (gp150) is identical to aminopeptidase N, J Clin Invest, 83, 1299, doi.org/10.1172/JCI114015 ; Y Luan (2007), The structure and main functions of aminopeptidase N, Curr Med Chem, 14, 639, doi.org/10.2174/092986707780059571 ; K Morikawa (1989), Bestatin, an inhibitor of aminopeptidase B, suppresses the proliferation and differentiation of human B-cells in vitro, Int J Immunopharmacol, 11, 905, doi.org/10.1016/0192-0561(89)90112-4 ; B Nelson (1998), Biology of the interleukin-2 receptor, Adv Immunol, 70, 1, doi.org/10.1016/S0065-2776(08)60386-7 ; K Ota (1992), Clinical trials of bestatin for leukemia and solid tumors, Biotherapy, 4, 205, doi.org/10.1007/BF02174207 ; T Otsuka (1988), Stimulatory effects of bestatin on human B-cell colony formation, Int J Immunopharmacol, 10, 587, doi.org/10.1016/0192-0561(88)90077-X ; G Pulido-Cejudo (1997), Bestatin-mediated inhibition of leucine aminopeptidase may hinder HIV infection, Antiviral Res, 36, 167, doi.org/10.1016/S0166-3542(97)00052-1 ; S Sasaki (1998), Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1, Clin Exp Immunol, 111, 30, doi.org/10.1046/j.1365-2249.1998.00466.x ; K Shibuya (1991), Enhancing effect of ubenimex (bestatin) on proliferation and differentiation of hematopoietic progenitor cells, and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation, Biomed Pharmacother, 45, 71, doi.org/10.1016/0753-3322(91)90125-D ; H Suda (1976), The structure of bestatin, J Antibiot (Tokyo), 29, 100. ; S Tsukagoshi (1987), A new antitumor drug with immunomodulating activity, ubenimex (bestatin), Gan To Kagaku Ryoho, 14, 2385. ; H Umezawa (1976), Bestatin, an inhibitor of aminopeptidase B produced by actinomycetes, J Antibiot (Tokyo), 29, 97. ; A Urabe (1993), Ubenimex in the treatment of acute nonlymphocytic leukemia in adults, Ann Hematol, 67, 63, doi.org/10.1007/BF01788128 ; Y Wakabayashi (1991), Effects of bestatin (Ubenimex) on human T-cell colony formation, Anticancer Drugs, 2, 39, doi.org/10.1097/00001813-199102000-00005 ; N Weissmann (1985), Mitogenic potentials of bestatin, amastatin, arphamenines A and B, FK-156 and FK-565 on spleen lymphocytes, J Antibiot (Tokyo), 38, 772. ; H Yamagishi (1991), Bestatin administration and the change in cellular immunity, Biomed Pharmacother, 45, 117, doi.org/10.1016/0753-3322(91)90131-C